Dr. Noushin Dianat, Cyprio’s CEO and specialist in cell biology and innovative therapies, obtained her doctorate from Université Paris Sud in 2013. Her works were mostly focalized on in vitro disease modeling, somatic cells reprogramming into iPSCs, and hepatic and biliary differentiation of human pluripotent stem cells. In 2014 she joined ESPCI where she established and characterized HepatoPearl model. She is author of 2 patents, 8 articles and awardee of multiple international grants.
Dr. Pablo Ibáñez is senior researcher in Cyprio. After a Ph. D on parkinson’s disease (PD) genetics, he developed C. elegans models for uncovering PD related genes. He moved on developing a method and instrument for meganuclease based genome engineering in C. elegans, prior to join the ESPCI in 2014 to optimize the RNA-Seq on HepatoPearl. He is author of 15 international articles.
Dr. Raif Eren Ayata is research scientist in Cyprio. He obtained his Master of Science degree in pharmaceutical technology from Hacettepe University/Turkey and PhD degree in pharmaceutical sciences from Laval University/Canada. He is specialist of skin tissue engineering, topical drug delivery and percutaneous absorption.